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ABSTRACT Cutaneous melanoma (M) can develop through two pro-
gression phases: the radial growth phase of M (RGPM) and the verti-
cal one. this distinction has a practical relevance in defining lesions 
with potential for a metastatic course. We analyzed the morphologi-
cal attributes (intraepidermal proliferation type, inflammatory in-
filtrate, mitogenicity, Breslow thickness, Clark level, ulceration) and 
the immunohistochemical profile (S100, Melan A, HMB45, p16INK4a, 
CD117, Ki67, Cyclin D1, E Cadherin, Podoplanin) of 12 microinvasive 
RGPMs in absence of regression, with almost 10 years of follow-
up. Immunohistochemistry (IHC) revealed that S100, Melan A, and 
HMB45 maintain a high expression in M cells in both epidermal and 
dermal compartments. Interestingly, an overexpression of p16INK4a 
in the nests of dermal microinvasion has been ascertained in all our 
cases. On the other hand, we found an attenuation of expression 
for CD117, Ki67, Cyclin D1, and E Cadherin in the migration phase 
from the epidermis to dermis. Each phase in M progression appears 
characterized by a specific immunohistochemical profile, as a result 
of molecular alterations. the long-term follow-up of our case series 
showed that microinvasive RGPM without regression is not tumori-
genic and is devoid of metastatic potential; therefore, its accurate 
categorization is important. Conversely, microinvasive RGPM with 
regression should be classified as melanocytic tumor with uncertain 
biological potential. IHC for p16INK4a can be helpful in the diagno-
sis of microinvasive M on challenging cutaneous biopsies. Moreover, 
it can be applied as an immunohistochemical discriminator to dis-
tinguish microinvasive RGPM from in situ RGPM and microinvasive 
RGPM from dysplastic nevi.
KEY WORDS: melanoma, radial growth phase (RGP), p16INK4a (cd-
kn2a), CD117 (c-Kit), histology, immunohistochemistry
INTRODUCTION
Primary cutaneous melanoma (M) can develop 
through two well recognizable phases: the radial 
growth phase M (RGPM) and the vertical growth 
phase M (VGPM). this distinction derives from the 
concept of tumor progression and has a practical rel-
evance in defining lesions with metastatic potential. 
the first complete and accurate description of RGPM 
was reported by Clark et al. in 1975, who described it 
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as a “lesion composed of melanoma cells within the 
epidermis and papillary dermis with a lack of bio-
logic potential for metastasis in spite of invasion of 
the papillary dermis for some years” (1). the lesion is 
in fact characterized by a proliferation of malignant 
melanocytes confined to the epidermis (in situ M), 
or the malignant melanocytes invade the papillary 
dermis (microinvasive M), but, by definition, there is 
no evidence of tumor lump formation (2). RGPM is 
considered to lack metastatic competence (2,3). In 
microinvasive RGPM, the migration of neoplastic me-
lanocytes into papillary dermis is often termed “in-
vasion”, but it is not necessarily accompanied by the 
acquisition of the capacity to survive, proliferate, or 
invade vessels and stroma (4,5). On the other hand, 
VGPM is characterized by the presence of true tumor 
nodules in the dermis. the two most important his-
tologic features that help define the dermal invasion 
in VGPM are: dermal nests larger than any epidermal/
junctional nest (expansive growth) and the presence 
of mitotic activity in the dermal component (6). All 
Ms at the third Clark level or deeper can be classified 
as VGPMs. For lesions at the second Clark level, the 
distinction between RGPM and VGPM can be difficult 
to make, and while inter-observer agreement among 
experienced dermatopathologists is good, concor-
dance among non-specialists or less experienced ob-
servers is poor. In the present paper, we analyze the 
histopathological attributes and the immunohisto-
chemical profile of 12 microinvasive RGPMs without 
regression, emphasizing that an accurate categoriza-
tion of this kind of lesion is extremely important be-
cause it leads to excellent patient survival.
PATIENTS AND METHODS 
the present study was a retrospective single-co-
hort study that included 12 cases of microinvasive 
RGPM, in absence of regression, diagnosed between 
2003 and 2005 at the Institute of Pathology in Rov-
ereto (Italy), with almost 10 years of follow-up and 
paraffin blocks available for immunohistochemistry 
(IHC). We adopted reproducible inclusion criteria for 
microinvasive RGPM. 
Firstly, we defined microinvasive RGPM based on 
the presence of a few isolated melanoma cells or clus-
ters in the papillary dermis, numbering up to 15 cells 
in individual sections with dermal nests smaller than 
those seen in the overlying epidermal component. 
Each epidermal component was categorized as len-
tiginous or pagetoid (nested). An increased number 
of atypical melanocytes along the dermal-epider-
mal junction were considered “lentiginous prolifera-
tion”. In this case, the melanocytes were contiguous 
to each other and the proliferation was continuous; 
the granules of pigment were often abundant and 
coarse, while the borders of the lesion were usually 
impalpable. Conversely, the pagetoid proliferation 
corresponded to an increased number of atypical 
epithelioid melanocytes, arranged singly and in nests 
near to the dermal-epidermal junction, with upward 
extension into the stratum corneum. In this instance, 
the nuclear atypia was moderate to severe; the bor-
ders of the lesion were often palpable. 
Secondly, we defined regression as an area of 
increased vascularity and delicate fibroplasia in the 
papillary dermis, presenting a dermal infiltrate of 
lymphocytes and melanophages in absence of mela-
noma cells. 
In our study, we excluded 25 cases of microinva-
sive RGPM with regression, 15 cases in which stained 
tissue sections were technically poor (8 cases with no 
residual invasion on IHC stained slides and 7 cases in 
which no consensus could be reached) and 15 cases 
in which the follow-up was not possible. Moreover, 
we considered only complete excisional biopsies and, 
therefore, a further 13 cases of microinvasive RGPM 
were excluded because the shave biopsies did not in-
clude complete tumors. All the slides were originally 
reviewed for routine histological attributes by authors 
without knowing patient outcomes. the reviewed at-
tributes included: proliferation type of the intraepi-
dermal component of microinvasive RGPM, band-like 
inflammatory infiltrate, dermal mitotic figures/mm2 
(mitogenicity), Breslow thickness, Clark level and ul-
ceration. Eighteen sections were cut for each paraffin 
block (sub-seriation). After deparaffinization, hydra-
tion, endogenous peroxidase blocking, and heat-
induced antigen retrieval, the tissue sections were 
incubated for 30 minutes at room temperature with 
anti-S100 protein (clone S1/61/69, prediluted; Leica 
Biosystems, Wetzlar, Germany), anti-Melan A (clone 
A103, prediluted; Leica), anti-Melanosome (clone 
HMB45, prediluted; Leica), anti-p16INK4a (clone E6H4, 
prediluted; Leica), anti-CD117 (clone t595, predilut-
ed; Leica), anti-Ki67 antigen (clone MM1, prediluted; 
Leica), anti-Cyclin D1 (clone P2D11F11, prediluted; 
Leica), anti-E Cadherin (clone 36B5, prediluted; Leica), 
and anti-Podoplanin (clone D2-40 prediluted; Leica). 
A biotinylated secondary antibody was applied, and 
the staining product was detected with avidin-biotin 
complex (ABC) against a hematoxylin counterstain. 
Detection of the staining reaction was achieved by 
an enzyme-conjugated polymer complex adapted 
for automatic stainers from Leica Biosystems, with 
3-3’ diaminobenzidine tetrahydrochloride (DAB) or 
new fuchsine as chromogens. Each immunoreaction 
was evaluated by all authors and scored using a semi-
quantitative method as follows: negative staining (-), 
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low positive staining (+), moderate positive staining 
(++), and high positive staining (+++). the macro-
scopic features of the lesions were also considered, 
according to the ABCDE rule (asymmetry, border ir-
regularity, color variegation, diameter, and evolution 
in time).
RESULTS
From the analysis of our case series, all microin-
vasive RGPMs were asymptomatic with no history 
of change, not all lesions were symmetric and flat or 
slightly raised, and they could be identified only by 
an alert physician. the age at the time of diagnosis 
ranged from 42 to 72 years with a mean of 59 years. 
the mean Breslow thickness was 0.4 mm (range 0.2-
1.1 mm); all the lesions reached the second level of 
Clark. the epidermal component was pagetoid in 8 
cases, while it was lentiginous in the remaining cases 
(Figure 1). the band-like inflammatory infiltrate was 
absent in 5 cases, not brisk in 2 cases, and brisk in the 
remaining cases. In 3 cases, 1 mitosis/mm2 was ob-
served, and in 1 case 2 mitotic figures/mm2 were ob-
served (no mitoses in the remaining cases). the length 
varied from 0.3 cm to 2 cm (mean 0.9 cm), while the 
width measured from 0.2 cm to 1.2 cm (mean 0.7 cm). 
Ulceration, nodules, and regression were absent (Fig-
ure 2). the immunohistochemical findings, reported 
in table 1, revealed that S100 protein, Melan A, and 
Melanosome (HMB45) maintained a high expression 
in M cells in both epidermal and dermal compart-
ments (Figure 1). Interestingly, an overexpression of 
p16INK4a in the nests of dermal microinvasion was 
found in all our cases (Figure 3). Conversely, an at-
tenuation of expression in the migration phase from 
the epidermis to dermis was observed for CD117 (c-
Kit), Ki67 antigen, Cyclin D1, and E Cadherin (Figure 
1). the immunohistochemical assay for podoplanin, 
Figure 1. Imaging sequence of lentiginous (left row) versus 
nested (right row) type microinvasive radial growth phase 
melanoma (RGPM), in absence of regression, with related 
immunohistochemical profiles. (A) lentiginous type, hema-
toxylin and eosin (H&E) ×4; (B) nested type, H&E ×4; (C) anti-
S100 protein, clone S1/61/69, prediluted, Leica Biosystems, 
Wetzlar, Germany, ×10; (D) anti-Melan A, clone A103, predi-
luted, Leica, ×4; (E) and (F) anti-CD117 clone t595, predi-
luted, Leica, ×4 and ×10; (G) and (H) anti-Ki67, clone MM1, 
prediluted, Leica, ×10 and ×10; (I) and (J) anti-Cyclin D1, 
clone P2D11F11, prediluted, Leica, ×10 and ×10; (K) and (L) 
anti-E Cadherin, clone 36B5, prediluted, Leica, ×4 and ×10).
Figure 2. Microinvasive radial growth phase melanoma 
(RGPM) with regression: the yellow arrows point to nests of 
papillary dermal microinvasion: (A), hematoxylin and eosin 
(H&E) ×10. Areas of complete (red circle) or partial (yellow 
oval) regression can be observed: (B), H&E ×4. this histo-
pathological variant has with unknown biological potential 
and for this reason it has been excluded by our series.
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Figure 3. Microinvasive radial growth phase melanoma 
(RGPM) without regression: nests of papillary dermal micro-
invasion, which evoke a superficial band-like lymphocytic 
reaction, are indicated with yellow arrows: (A), hematoxylin 
and eosin (H&E) ×10. the intense brown-stained neoplas-
tic nests overexpress p16INK4a protein: (B), red arrows: as 
revealed by immunohistochemical (IHC) assay: (B), clone 
E6H4, prediluted; chromogen 3-3’ diaminobenzidine tetra-
hydrochloride, ×10). A nest of dermal microinvasion (yellow 
arrow) is well red-stained by IHC for anti-Melan A: (C), clone 
A103, prediluted; chromogen new fuchsine, ×10. At higher 
magnification, the same nest (red arrow) shows an overex-
pression of p16INK4a protein if compared to the above epi-
dermal compartment: (D), clone E6H4, prediluted, ×20).
dermal microinvasion. this finding appears to be a 
valuable aid in the diagnosis of microinvasive RGPM 
and agrees with the results reported by Strickler et al. 
(7). the authors have in fact examined the association 
of p16INK4a, Wt1, and Fli-1 in 18 cases of RGPM and 
in 15 cases of VGPM: p16INK4a staining was strong 
in 15 RGPM (83%), Wt1 in 17 RGPM (100%), and Fli-1 
at least focally in 6 of 18 RGPM (33%). the infiltrative 
component of VGPM stained positively for Fli-1 in 9 
of 14 cases (64%), intensely for Wt1 in 10 of 14 cases 
(71%), and strongly for p16INK4a in only 2 of 15 cases 
(13%). RGPM tends to evoke a striking host response 
in the papillary dermis, typically a dense cellular in-
filtrate of lymphocytes and monocytes/macrophages 
in a perivascular or band-like fashion. In our series, 
the band-like inflammatory infiltrate was brisk in 5 
cases, not brisk in 2 cases, and absent in the remain-
ing cases. When a brisk infiltrate is encountered, the 
IHC for melanocytic cells, such as Melan A, HMB45, 
or S100, allows detection of single melanoma cells 
scattered among the inflammation in the papillary 
dermis, facilitating the achievement of a conclusive 
diagnosis.
In revising our cases, we noted that regression in 
RGPM can be complete or partial and diffuse or focal. 
Complete regression can be defined as an area within 
the melanoma where there is fibroplasia and usually 
lymphocytic infiltrate, often with melanophages and 
prominent vessels, but without melanoma cells in the 
dermis. Adjacent to this area of regressive fibroplasia, 
melanoma cells may be found in the epidermis, der-
mis, or in both. Partial regression is the disappearance 
of parts of the neoplasia without complete replace-
ment of the tumor by inflammatory cells, melano-
phages, and fibrosis, and with focal persistence of 
melanoma cells. theoretically, diffuse regression oc-
curs when the entire tumor is affected by regression, 
while in focal regression the regression can only be 
found in a segment of the tumor. According to Guerry 
et al. (4), RGPM in absence of regression is biologically 
indolent and lacks metastatic competence. Some 
authors agree that RGPM regression is an adverse 
prognostic factor (8-9). Yun et al. (10) demonstrated 
that the adverse effect of RGPM regression is medi-
ated through the increased lymphatic vessel density 
and/or lymphatic invasion in the area of complete 
regression, whereas a partial regression does not ap-
pear to be associated with worse prognosis. On the 
other hand, Kaur et al. (11) proposed a histopatho-
logical staging system for regression, concluding that 
regression is associated with a favorable prognosis in 
thin Ms. An Australian study on 1716 patients with 
RGPM showed metastases in 67 patients (3.9%), in 
all of whom M showed regression in their primary tu-
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performed on every case, did not reveal any lymphat-
ic invasion.
DISCUSSION
In microinvasive RGPM the recognition of papil-
lary dermal microinvasion is facilitated by observing 
tumor cells separated from the junctional compo-
nent through the interposition of dermal collagen, 
generally beneath the plane of the epidermal rete 
ridges or basal layer of the epidermis. Problems in the 
classification of dermal migration arise on histologi-
cally indeterminate cases, or when, as result of cross 
sections, large nests of melanocytes connected to the 
epidermis or adnexal structures appear free in the der-
mis. According to our findings, the IHC for p16INK4a 
protein and Melan A (or HMB45 or S100), together 
with serial sectioning, can resolve these disputes. In 
the analysis of our case series of microinvasive RGPM 
at the second Clark level, a precursor of tumorigenic 
VGPM, we constantly detected an immunohisto-
chemical overexpression of p16INK4a in the nests of 
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mors (12). In our opinion, the variable results in these 
reported studies may be explained by the different 
criteria used to define regression (complete vs partial; 
diffuse vs focal). In the present study, we have exclud-
ed 25 cases of microinvasive RGPM with regression 
because we believe that microinvasive RGPM with re-
gression should be not considered non-tumorigenic, 
but rather a variant of RGPM with uncertain biologi-
cal potential (13). For this reason, in these cases the 
use of the term “non-tumorigenic” is to be avoided 
and sentinel node biopsy should be considered, in-
dependently from the Breslow thickness.
Starting from the assumption that the main genes 
implicated in the pathogenesis of melanoma are CD-
KN2A, encoding for p16INK4a, and several transcript 
variants such as p14ARF, C-KIt, MItF (microphthalmia-
associated transcription factor), N-RAS, and B-RAF 
(14), we investigated the first two genic pathways 
immunohistochemically, being the two most suitable 
to date from an immunohistochemical point of view, 
together with the cell cycle (Ki67, Cyclin D1) and in-
tercellular adhesion (E Cadherin).
Our immunohistochemical results have demon-
strated an overexpression of p16INK4a in the dermal 
compartment for microinvasive RGPM, but also an at-
tenuation of expression in the M cells for CD117, Ki67 
antigen, Cyclin D1, and E Cadherin during the migra-
tion phase from the epidermis to the dermis. these 
findings support the concept that each phase in M 
progression is characterized by a specific immuno-
histochemical profile as a result of molecular altera-
tions.
Firstly, the expression profile of CD117, the mast/
stem cell growth factor receptor, was decreased in the 
dermal compartment with respect to the epidermal 
one in all microinvasive RGPMs of our series. Similarly, 
Montone et al. (15) found that CD117 is expressed in 
normal melanocytes, benign nevi, dysplastic nevi, 
and non-tumorigenic RGPM but not in tumorigenic 
M and metastases. In the model of M progression 
(RGPM followed by VGPM), Alexeev et al. (16) hypoth-
esized that melanoma cells lose CD117 expression 
to acquire proliferative advantage and escape from 
epidermal boundaries, and our results support this 
hypothesis.
Secondly, the proliferative activity in RGPM is 
practically confined to the lesional cells in the epi-
dermal compartment. the dermal microinvasive cells 
Table 1. Semi-quantitative immunohistochemical scoring for the epidermal (green) and dermal (red) com-
ponents of the 12 studied cases of microinvasive radial growth phase melanoma (RGPM) without regression. 
the relative ratios for each immuno-marker are shown in parenthesis
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IMMUNOHISTOCHEMICAL 
MARKER
EPIDERMAL COMPARTMENT                                 
(ratio)
DERMAL COMPARTMENT                                   
(ratio)
S100 protein +++ (12/12)
+++ 
(12/12)
Melan A +++ (12/12)
+++ 
(12/12)
Melanosome (HMB45) +++ (12/12)
+++ 
(12/12)
p16INK4a +     (2/12) ++ (10/12)
+++ 
(12/12)
CD117 (c-Kit) ++ (12/12) - (6/12) + (6/12)
Ki67 antigen ++  (12/12) - (2/12) + (10/12)
Cyclin D1 ++ (12/12) - (9/12) + (3/12)
E Cadherin ++ (12/12) - (10/12) + (2/12)
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show low reactivity for Ki67 antigen because the 
melanoma cells are not tumorigenic in RGPM without 
regression. the immunohistochemical assay for Ki67 
antigen can thus be so considered a useful test to 
exclude potentially tumorigenic M. Similar findings 
have been reported by others authors (17-18). For 
example, Gimotty et al. (19) demonstrated that der-
mal Ki67 expression was lower than epidermal Ki67 
expression in RGPM and that dermal Ki67 expres-
sion and dermal mitotic rates were higher in VGPM in 
comparison with RGPM. these data support that only 
tumorigenic M exhibits significant proliferative activ-
ity in the dermis.
thirdly, Cyclin D1 maintained the same expression 
profile of CD117, Ki67, and E Cadherin in our immu-
nohistochemical investigation. Alonso et al. (20) ex-
amined 165 M samples from 88 patients correspond-
ing to RGPM, VGPM, and metastases. the authors 
found that cyclin D1 was expressed in 48% of RGPMs 
(12 of 25), with significant loss of expression in VGPM. 
Alonso et al. showed that melanoma cells progress 
through the deregulation of the molecular mecha-
nisms, controlling proliferation and programmed 
death, in accord with the article by Molumbres and 
Barbacid (21).
Fourthly, the adhesiveness loss of melanoma cells 
to both basal laminae and adjacent keratinocytes, 
consequent to a downregulation of the cell adhesion 
protein E Cadherin (22), promoted tumor microinva-
sion in RGPMs in our case series.
CONCLUSION
Long-term follow-up in our case series has shown 
that microinvasive RGPM without regression is not 
tumorigenic and is devoid of metastatic potential. 
Conversely, microinvasive RGPM with regression 
should be classified as melanocytic tumors with un-
certain biological potential. the IHC for p16INK4a 
protein allows confirmation of dermal microinvasion 
and can be helpful in the diagnosis of microinvasive 
M in cutaneous biopsies of difficult interpretation. In 
particular, it can be applied as an immunohistochem-
ical discriminator to distinguish microinvasive RGPM 
from in situ RGPM and microinvasive RGPM from dys-
plastic nevi.
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